Sanofi upgrades 2021 guidance once again – Dupixent drives growth

On Thursday morning, French Sanofi published its report for the third quarter of the year, and in connection with the release, the pharmaceutical company upgrades its earnings-per-share expectations for the full year.
Photo: Charles Platiau/Reuters/Ritzau Scanpix
Photo: Charles Platiau/Reuters/Ritzau Scanpix
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN

The French pharmaceutical company Sanofi has upgraded its 2021 financial guidance for earnings per share (business EPS), it reports in a press release on Thursday morning.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading